Hepatitis C (HCV) Treatment and SVR12: The Gap Between Clinical Trials and Community Practice With DAA Therapy: 1045Anjum, SarahSultan, TahaTariq, ZohhaAlam, ImtiazOfficial journal of the American College of Gastroenterology | ACG
鉴于原研欧盟组合的百万天价,近日,中、老两国权威医疗机构联合推广和实施的“丙肝康复计划(Hepatitis C Treatment Programme)”给众多想要获得DAAs的国内丙肝患者多了一个可靠选择。 “丙肝康复计划”是老挝卫生部基于今年5月在老挝上市的丙肝新药——Sofeni(索菲尼)和Dactinna(达可汀纳)推出的国家级医疗项目,上述两款...
Despite the remarkable improvements in pharmacologic treatment efficacy for hepatitis C (HCV) reported in published clinical trials, published research suggests that, in "real-world" patient care, these medical outcomes may be difficult to achieve. This review was undertaken to summarize recent experienc...
The Editors at Hepatitis CentralSeptember 22, 2010 Print this pageA Spanish study finds that even if a sustained viral response is not achieved with combination therapy, those who had a partial response to Hepatitis C treatment fared better than those with no response at all. ...
HCV, hepatitis C virus. Table 2. Reasons for non-response, pooled. Reasons for non-response8-week G/P therapy (n = 965)12-week G/P therapy (n = 1,076) Breakthrough, n (%) 2 (0.2)† 1 (<0.1)‡ Relapse, n (%) 7 (0.7)δ 3 (0.3)||,¶ Non-virologic ...
BACKGROUND: Randomized clinical trials (RCTs) of interventions for the hepatitis C virus have historically used sustained virological response (SVR) at 24 weeks after treatment (SVR24) as the key effect measure. However, recent RCTs investigating the efficacy of new direct acting agents (DAAs) ...
12. Fernandez Carrillo C, Lens S, Llop E, et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the heap-C registry. Hepatology, 2017, 65: 1810-1822. ...
Treatment of Chronic Hepatitis C - SVR Rates and Compliance with Conventional Interferon Therapy and Factors Influencing Response Rates: 316Nawaz, ArifChaudhry, AsadRiaz, MuhammadYousaf, MuhammadAlvi, AftabAhmed, AsimMustafa, AhmedKhan, HebaKhan, Ammarah...
Summary. Hepatitis C virus genotype 4 (HCV-4) infection is progressing in Europe, where epidemiology and sustained virological response (SVR) seem to be di... D Roulot,V Bourcier,V Grando,... - 《Journal of Viral Hepatitis》 被引量: 189发表: 2010年 Treatment of hepatitis C virus genotyp...
Patients' Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection sustained virologic response [SVR]); weeks on an additional, third medicine (i.e. a DAA); risk of a severe rash; risk of severe anemia; and ... Dr,Teresa,L.,... - 《Patie...